Cedar Pollen Allergy pipeline therapeutics constitutes close to 8 molecules. Out of which approximately 7 molecules are developed by Companies and remaining by the Universities/Institutes. latest report Cedar Pollen Allergy – Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Cedar Pollen Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Request for sample @ https://marketreportscenter.com/request-sample/438515
Cedar Pollen Allergy Cedar allergy is a seasonal allergy brought on by an allergic reaction to the pollen from mountain cedar trees. Symptoms include runny nose, itchy and watery eyes, nasal blockage and sneezing. Some suffers also complain of fatigue, mild headache, facial discomfort, sore throat, partial loss of smell and the sensation of ear plugging. Treatment includes antihistamines and decongestants. The molecules developed by Companies in Pre-Registration, Phase I, Preclinical and Discovery stages are 2, 2, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.
Check Discount on report @ https://marketreportscenter.com/request-discount/438515
Furthermore, this report also reviews of key players involved in therapeutic development for Cedar Pollen Allergy and features dormant and discontinued projects. Driven by data built using data and information sourced from Our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
For more details of report, table of content, purchase copy of report visit https://marketreportscenter.com/reports/438515/cedar-pollen-allergy-pipeline-review-h2-2016
You can also reach me if you have any questions or need any assistance
Market Reports Center